Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 797

1.

IL-28 elicits antitumor responses against murine fibrosarcoma.

Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M.

J Immunol. 2007 Apr 15;178(8):5086-98.

PMID:
17404291
[PubMed - indexed for MEDLINE]
Free Article
2.

IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.

Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H.

J Immunol. 1998 Feb 15;160(4):1742-9.

PMID:
9469432
[PubMed - indexed for MEDLINE]
Free Article
3.

Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs.

Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B.

Blood. 1994 Mar 1;83(5):1289-98.

PMID:
8118032
[PubMed - indexed for MEDLINE]
Free Article
4.

Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.

Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T.

Int Immunol. 1995 Jul;7(7):1135-45.

PMID:
8527411
[PubMed - indexed for MEDLINE]
5.

Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.

Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H.

J Immunol. 2007 Jun 15;178(12):7571-80.

PMID:
17548592
[PubMed - indexed for MEDLINE]
Free Article
6.

Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.

Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H.

Cancer Res. 2000 Sep 1;60(17):4838-44.

PMID:
10987295
[PubMed - indexed for MEDLINE]
Free Article
7.

In vivo antitumor activity of interleukin 21 mediated by natural killer cells.

Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, Kim G, Leonard WJ, Hwu P.

Cancer Res. 2003 Dec 15;63(24):9016-22.

PMID:
14695220
[PubMed - indexed for MEDLINE]
Free Article
8.

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.

Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ, Collins M, Dunussi-Joannopoulos K.

J Immunol. 2003 Jul 15;171(2):608-15.

PMID:
12847225
[PubMed - indexed for MEDLINE]
Free Article
9.

Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells.

Xiang J, Chen Z, Huang H, Moyana T.

Leuk Res. 2001 Oct;25(10):909-15.

PMID:
11532525
[PubMed - indexed for MEDLINE]
10.

Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.

Eguchi J, Hiroishi K, Ishii S, Mitamura K.

Cancer Immunol Immunother. 2003 Jun;52(6):378-86. Epub 2003 Mar 18.

PMID:
12739068
[PubMed - indexed for MEDLINE]
11.

Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells.

Sadanaga N, Nagoshi M, Lederer JA, Joo HG, Eberlein TJ, Goedegebuure PS.

J Immunother. 1999 Jul;22(4):315-23.

PMID:
10404433
[PubMed - indexed for MEDLINE]
12.

Interferon-gamma-inducing factor elicits antitumor immunity in association with interferon-gamma production.

Tan J, Crucian BE, Chang AE, Aruga E, Aruga A, Dovhey SE, Tanigawa K, Yu H.

J Immunother. 1998 Jan;21(1):48-55.

PMID:
9456436
[PubMed - indexed for MEDLINE]
13.

Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.

Li T, Harada M, Tamada K, Abe K, Nomoto K.

Anticancer Res. 1997 Nov-Dec;17(6D):4259-68.

PMID:
9494518
[PubMed - indexed for MEDLINE]
14.

Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.

Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang N, Mahvi DM.

Hum Gene Ther. 2001 Jan 20;12(2):149-60.

PMID:
11177552
[PubMed - indexed for MEDLINE]
15.
16.

Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.

Hafner M, Falk W, Echtenacher B, Männel DN.

Eur Cytokine Netw. 1999 Dec;10(4):541-8.

PMID:
10586121
[PubMed - indexed for MEDLINE]
17.

NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.

Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH.

Int J Cancer. 2004 Apr 20;109(4):499-506.

PMID:
14991570
[PubMed - indexed for MEDLINE]
18.

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.

Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP, Ferrini S.

J Immunol. 2004 Feb 1;172(3):1540-7.

PMID:
14734732
[PubMed - indexed for MEDLINE]
Free Article
19.

Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.

Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L.

J Immunother Emphasis Tumor Immunol. 1993 Oct;14(3):191-201.

PMID:
7905286
[PubMed - indexed for MEDLINE]
20.

Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.

Aruga A, Aruga E, Cameron MJ, Chang AE.

J Leukoc Biol. 1997 Apr;61(4):507-16.

PMID:
9103238
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk